Risankizumab in Psoriasis and Crohn’s Disease: A Comprehensive Review

Risankizumab, a humanized monoclonal antibody that targets interleukin-23 (IL-23), has emerged as a viable treatment option for psoriasis and Crohn's disease. IL-23 plays an important role in the development of several chronic inflammatory diseases, triggering the immunological response that underpins their clinical symptoms. Risankizumab has shown great effectiveness in decreasing skin lesions in psoriasis, with long-term benefits to the severity of the disease and individual quality of life. Similarly, in Crohn's disease, research trials have demonstrated its ability to elicit and maintain remission, providing a novel therapy option for individuals with moderate to severe illness. This review explores the mechanism of action, clinical effectiveness, safety profile, and long-term results of risankizumab in the treatment of psoriasis and Crohn's disease, offering a thorough summary of its function in treatment strategies.